Publication | Closed Access

First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial

First-line PenpulimabPlacebo-controlled Phase 3MedicineMetronomic TherapyPathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology